Previous Close | 3.0600 |
Open | 3.0700 |
Bid | 2.8100 x 2200 |
Ask | 2.8100 x 1100 |
Day's Range | 2.7600 - 3.1800 |
52 Week Range | 2.7600 - 9.8100 |
Volume | |
Avg. Volume | 393,095 |
Market Cap | 144.688M |
Beta (5Y Monthly) | 1.15 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.9810 |
Earnings Date | Aug 03, 2022 - Aug 08, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 13.83 |
Subscribe to Yahoo Finance Plus to view Fair Value for JNCE
CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will participate at the following upcoming investor conferences: H.C. Wainwright Global Investment Conference: Presentation will be available for on-demand viewing starting Tuesday, May 24, 2022 at 7:00 a.m. ET. Cowen’s 3rd Annual Oncology Inn
The analysts covering Jounce Therapeutics, Inc. ( NASDAQ:JNCE ) delivered a dose of negativity to shareholders today...
Some stocks are best avoided. We don't wish catastrophic capital loss on anyone. Imagine if you held Jounce...